GlobeNewswire Inc.··NaEupraxia Raises $63.2M, Eyes 2028 as Cash-Runway Extends Despite Rising Losses
Eupraxia Pharmaceuticals closed $63.2M offering, boosting cash to $80.5M with runway through H2 2028. Q4 losses doubled to $16.7M amid clinical progress in eosinophilic esophagitis treatment.
EPRXpublic offeringdrug delivery